Dr. Lambert highlights the safety focus of SAT-3247 in phase 1 trials, ensuring the drug’s translation from preclinical to clinical settings. The study aimed to validate safety in both patients and healthy volunteers, crucial for complex diseases like Duchenne Muscular Dystrophy.Implications of these promising phase 1 results pave the way for advancing to phase 2 […]